Cargando…
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
Repeated bouts of acute and chronic lung infections are responsible for progressive pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to respiratory failure and death. Pseudomonas aeruginosa is the archetypical CF pathogen, causes chronic infection in 70% of ind...
Autores principales: | Lam, John, Vaughan, Steven, Parkins, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836451/ https://www.ncbi.nlm.nih.gov/pubmed/24324354 http://dx.doi.org/10.4137/CCRPM.S10592 |
Ejemplares similares
-
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020) -
Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017) -
Ease of use of tobramycin inhalation powder compared with nebulized
tobramycin and colistimethate sodium: a crossover study in cystic fibrosis
patients with pulmonary Pseudomonas aeruginosa
infection
por: Greenwood, James, et al.
Publicado: (2017) -
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014) -
Tobramycin inhalation powder for the treatment of pulmonary
Pseudomonas aeruginosa infection in patients with cystic
fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)